Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company developing new and exciting approach to treat cancer with results from over 200 patients and partnerships with major pharmaceutical companies visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Lewis H. Bender, Founder, President, and CEO, rings the Closing Bell.